Skip to main content
Log in

Treatment of heart failure with a normal ejection fraction

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Treatment of diastolic heart failure is divided into acute and chronic management. During acute management, the focus should be treatment of the presenting syndrome, including correction of volume overload, treating hypertension, alleviating ischemia, and controlling tachyarrhythmias. Therefore, acute treatment should include several components: treating volume overload with sodium restriction and diuretics; treating ischemie heart disease with antiplatelet therapy, anticoagulants, and β blockers; treating hypertension aggressively, using multiple agents if necessary; and treating atrial tachyarrhythmias such as atrial fibrillation with rate-controlling agents, such as β blockers and possibly nondihydropyridine calcium channel blockers such as diltiazem and verapamil. Antiarrhythmic agents with or without electrical cardioversion may be necessary. Thoroughly evaluate and manage extracardiac precipitants such as anemia and renal failure. Chronic management should also focus on precipitating factors, for which adequate control of hypertension is paramount. Patient education regarding dietary and medication compliance and lifestyle changes is also important. If ischemic heart disease is present, aggressive anti-ischemic therapy is necessary, including revascularization when indicated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. Zile MR Baku CF, Gaasch WH: Diastolic heart failure—abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004, 350:1953–1959.

    Article  PubMed  CAS  Google Scholar 

  2. Gaasch WH, Zile MR: Left ventricular diastolic dysfunction and diastolic heart failure. Annu Rev Med 2004, 55:373–394.

    Article  PubMed  CAS  Google Scholar 

  3. Aurigemma GP, Gaasch WH: Diastolic heart failure. N Engl J Med 2004, 351:1097–1105. Comprehensive up-to-date review of DHF with thorough discussion of pathophysiology, diagnosis, and treatment.

    Article  PubMed  CAS  Google Scholar 

  4. Redfield MM: Understanding “diastolic” heart failure. N Engl J Med 2004, 350:1930–1931.

    Article  PubMed  CAS  Google Scholar 

  5. Dahlstrom U: Can natriuretic peptides be used for the diagnosis of diastolic heart failure? Eur J Heart Fail 2004, 6:281–287.

    Article  PubMed  CAS  Google Scholar 

  6. Hunt SA, Baker DW, Chin MH, et al.: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. J Am Coll Cardiol 2001, 38:2101–2113. Most recent guidelines for diagnosis and management of HF. Excellent reading on diagnosis and pharmacologic management of systolic HF, although considerable discussion on DHF is available.

    Article  PubMed  CAS  Google Scholar 

  7. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. The Beta-Blocker Evaluation of Survival Trial Investigators [no authors listed]. N EnglJ Med 2001, 344:1659–1667.

  8. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. CIBIS Investigators and Committees [no authors listed]. Lancet 1999, 353:3–13.

  9. Foody JM, Parrell MK, Krumholz HM: Beta-blocker therapy in heart failure. JAMA 2002, 287:883–889.

    Article  PubMed  CAS  Google Scholar 

  10. Weber KT: Aldosterone in congestive heart failure. N Engl J Med 2001, 345:1689–1697.

    Article  PubMed  CAS  Google Scholar 

  11. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709–717.

    Article  PubMed  CAS  Google Scholar 

  12. Pitt B, Remme WJ, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309–1321.

    Article  PubMed  CAS  Google Scholar 

  13. Papademetriou V, Dunlap ME: Management of systolic heart failure. Cardiol Rev 2003, 20(suppl):S12-S20.

    Google Scholar 

  14. Yusuf S, Pfeffer MA, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777–781. First large-scale, randomized, placebo-controlled clinical trial of a pharmacologic agent showing statistically significant benefit in DHF. Sets the stage for ongoing clinical trials in DHF.

    Article  PubMed  CAS  Google Scholar 

  15. Bhakta S, Dunlap ME: Angiotensin-receptor blockers in heart failure: evidence from the CHARM trial. Clev Clin J Med 2004, 71:665–673.

    Article  Google Scholar 

  16. Introduction [no authors listed]. Cardiol Rev 2003, 20(suppl):S2–S3.

  17. Krum H, Roecker EM, Mohacsi P, et al.: Effects of initiating carvedilol in patients with severe chronic heart failure. Results from the COPERNICUS study. JAMA 2003, 289:712–718.

    Article  PubMed  CAS  Google Scholar 

  18. Packer M, Bristow MR, Cohn JN, et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996, 334:1349–1355.

    Article  PubMed  CAS  Google Scholar 

  19. Bergstrom A, Anderson B, Edner M, et al.: Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler echocardiographic study (SWEDIC). Eur J Heart Fail 2004, 6:453–461.

    Article  PubMed  CAS  Google Scholar 

  20. Publication Committee for the VMAC Investigators: Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure. A randomized controlled trial. JAMA 2002, 287:1531–1540.

    Article  Google Scholar 

  21. Bradley DJ, Bradley EA, Baughman KL, et al.: Cardiac resynchronization and death from progressive heart failure. JAMA 2003, 289:730–740.

    Article  PubMed  Google Scholar 

  22. Kaneko Y: Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med 2003, 348:1233–1241.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bhakta, S., Dunlap, M.E. Treatment of heart failure with a normal ejection fraction. Curr Treat Options Cardio Med 7, 317–325 (2005). https://doi.org/10.1007/s11936-005-0042-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-005-0042-y

Keywords

Navigation